A Study Comparing the Effectiveness of First-Line (1L) Targeted Therapy (TT) and Immuno-oncology (I-O) Agents in BRAF v600 Mutated Metastatic Melanoma (BRAF+ MM) Patients

At a glance
Trial Overview
Trial Details
Interventions
Results
- Publications
Authors
Trial History
References

Trial Profile

A Study Comparing the Effectiveness of First-Line (1L) Targeted Therapy (TT) and Immuno-oncology (I-O) Agents in BRAF v600 Mutated Metastatic Melanoma (BRAF+ MM) Patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobimetinib (Primary) ; Dabrafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary) ; Vemurafenib (Primary)
Indications Malignant melanoma
Focus Therapeutic Use

Most Recent Events

30 Jun 2018 New trial record
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com